Invention Grant
- Patent Title: TET2 as a diagnostic and prognostic marker in hematopoietic neoplasms
-
Application No.: US15177055Application Date: 2016-06-08
-
Publication No.: US10662482B2Publication Date: 2020-05-26
- Inventor: Franck Viguie , Olivier Bernard , Michaela Fontenay , Christian Bastard , Francois Delhommeau , William Vainchenker
- Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , INSTITUT GUSTAVE-ROUSSY , ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS , CENTRE HENRI BECQUEREL , UNIVERSITE PARIS DESCARTES , UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) , UNIVERSITE PARIS-SUD
- Applicant Address: FR Paris FR Villejuil FR Paris FR Rouen FR Paris FR Paris FR Orsay
- Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),INSTITUT GUSTAVE-ROUSSY,ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS,CENTRE HENRI BECQUEREL,UNIVERSITE PARIS DESCARTES,UNIVERSITY PIERRE ET MARIE CURIE (PARIS 6),UNIVERSITE PARIS-SUD
- Current Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),INSTITUT GUSTAVE-ROUSSY,ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS,CENTRE HENRI BECQUEREL,UNIVERSITE PARIS DESCARTES,UNIVERSITY PIERRE ET MARIE CURIE (PARIS 6),UNIVERSITE PARIS-SUD
- Current Assignee Address: FR Paris FR Villejuil FR Paris FR Rouen FR Paris FR Paris FR Orsay
- Agency: Potomac Law Group, PLLC
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@26f41c3d com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@3bd55ba5
- Main IPC: C12Q1/6886
- IPC: C12Q1/6886 ; G01N33/574 ; A61K31/7068

Abstract:
The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.
Public/Granted literature
- US20160319370A1 TET2 AS A DIAGNOSTIC AND PRONOSTIC MARKER IN HEMATOPOIETIC NEOPLASMS Public/Granted day:2016-11-03
Information query
IPC分类: